In Phase C, participants will receive ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment till disorder progression or maybe the members are not able to tolerate the study drugs. - "Our study discovered the important part of the KLF16/MYC regulatory axis https://abbv-744-in-the-treatment47891.rimmablog.com/31420111/the-basic-principles-of-abbv-744-in-acute-myeloid-leukemia-aml